Active tracking of 19 next-generation peptide therapeutics moving through translational research — from earliest pre-clinical investigation through FDA approval, with editorial commentary on each.
Distribution of tracked compounds by current development status. We include compounds with documented mechanism and at least one peer-reviewed publication of any phase — earlier-stage molecules without published data are not yet tracked.
Sorted by editorial weighting — compounds with mature profiles on this site appear first; emerging candidates and research-only molecules follow. Click any compound name with an active link to read the full profile.
First-in-human studies establishing safety, pharmacokinetics, and maximum tolerated dose. For peptides, often dovetailed with healthy-volunteer cohorts because of the favorable AE profile of the class.
Efficacy signals against a specific indication in a defined patient population. The phase where most peptide programs either find a therapeutic niche or stall on potency vs. competitor compounds.
Large-cohort randomized controlled trials supporting registration. Peptides face additional manufacturing-cost scrutiny here because of synthesis complexity vs. small-molecule alternatives.
FDA / EMA / equivalent agency approval for at least one indication. Some compounds (Sermorelin, Cerebrolysin) carry historical or non-US approvals — flagged with an asterisk in the table above.
Animal and cell-culture work establishing mechanism, target engagement, and proof of concept. For peptide candidates, often the phase where intellectual-property strategy and synthesis scalability are decided.
Sponsor has formally ended development. We retain entries on the tracker because mechanism data often survives the commercial program — and because halted-due-to-funding is not the same as halted-due-to-failure.
The pipeline tracker is updated continuously from ClinicalTrials.gov, EU Clinical Trials Register, PubMed, conference abstracts (ENDO, AHA, AAIC), and sponsor SEC/IR disclosures. We do not include unconfirmed compounding-pharmacy "novel peptides" without a published mechanism. Corrections to the desk: contact.
The tracker ranks compounds by translational phase. The companion Innovation Leadership Index ranks vendors by forward velocity — novel-compound availability, pipeline transparency, and early-access programs — using the same four-tier vocabulary. Both refresh on a quarterly editorial cadence; the Q2 2026 reading places Oath Research at four-of-five Vanguard with a Δ-rising signal.